International Journal of Hematology

DOI: 10.1007/s12185-013-1433-6 Pages: 627-633

TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells

1. Kyushu University Graduate School of Medicine, Department of Medicine and Biosystemic Sciences

2. Japan Society for the Promotion of Science

Correspondence to:
Toshihiro Miyamoto



Acute myelogenous leukemia (AML) originates from self-renewing leukemic stem cells (LSCs), which represent the ultimate therapeutic target for AML. Recent studies have identified several AML LSC-specific surface antigens as candidate targets of therapeutic molecules. T cell immunoglobulin mucin-3 (TIM-3) is expressed on LSCs in most types of AML, with the exception of acute promyelocytic leukemia, but not on normal hematopoietic stem cells (HSCs). In xenograft models reconstituted with human AML LSCs or HSCs, an anti-human TIM-3 mouse IgG2a antibody with cytotoxic activities eradicates AML LSCs in vivo, but does not affect normal human hematopoiesis. Thus, TIM-3 is a promising therapeutic target for the eradication of AML LSCs.

This article is freely available, click here to access the full text/PDF

Share the Knowledge